

What comes next?

Newer-generation bioresorbable scaffold: Insights from shear stress simulations

**Patrick W. Serruys MD, PhD Imperial College, London,
United Kingdom**

**Yoshi Onuma, MD, PhD Erasmus MC, Rotterdam,
The Netherlands**

17:15-18:20



Friday October 13th



How improved scaffold technology can reduce clinical complication?

Shortcomings	Possible solution
<ul style="list-style-type: none"> ○ Low tensile strength, low radial force, recoil <> ○ thick strut, wide footprint 	<ul style="list-style-type: none"> • Increase tensile strength, good radial force -> thin strut (oriented PLLA, Arterius technology)
<ul style="list-style-type: none"> ○ Quadratic strut <ul style="list-style-type: none"> ○ Difficult to embed ○ Disturb laminar flow 	<ul style="list-style-type: none"> • Circular strut (Manli technology) <ul style="list-style-type: none"> • Easy to embed • Less disturbance of laminar flow
<ul style="list-style-type: none"> ○ Increase local viscosity and thrombogenicity ○ Main determinant of neointimal thickness and LA reduction 	<ul style="list-style-type: none"> • Use of biodegradable material non-thrombogenic: Magnesium
<ul style="list-style-type: none"> ○ Slow down the cell coverage 	<ul style="list-style-type: none"> • Circular strut
<ul style="list-style-type: none"> ○ Late structural discontinuity (dismantling) 	<ul style="list-style-type: none"> • Faster bioresorption (Manli technology)


How to increase tensile strength and radial force by altering molecular orientation of PLLA



- Tube wall thickness of $< 95 \mu\text{m}$ and even $< 75 \mu\text{m}$ can be achieved
- Scaffold tube thickness comparable to metallic DES

How to increase tensile strength and radial force by altering molecular orientation of PLLA


Material	PLLA	Oriented PLLA	Mg Alloy	Stainless Steel	Cobalt Chrome
Ultimate tensile strength (MPa)	~30-50	220-260	280	670	820-1200
Tensile Modulus (Gpa)	1.2-3.0	5-7	45	193	243
Elongation (%)	2-6	40-70	23	48	35-55




- **Tube wall thickness of < 95 μm and even < 75 microns can be achieved**
- **Scaffold tube thickness comparable to metallic DES**

Oriented polylactide, stronger and thinner strut Reducing the protrusion without increase of recoil

ArterioSorb from Arterius
Protrusion distance: $89 \pm 7 \mu\text{m}$




Absorb BVS from Abbott
Protrusion distance: $150 \pm 9 \mu\text{m}$



Scaffold	Lumen diameter (mm)	Balloon-artery ratio	Scaffold-artery ratio	Acute recoil (%)
Arteriosorb-95 (n=31)	2.91 ± 0.17	1.10 ± 0.06	1.06 ± 0.05	3.01 ± 5.06


Reduced struts protrusion , reduces low-shear stress (dark-blue color), reduces risk of thrombus peri-strut







How improved scaffold technology can reduce clinical complication?

Shortcomings	Possible solution
<ul style="list-style-type: none"> ○ Low tensile strength, low radial force, recoil <> ○ thick strut, wide footprint 	<ul style="list-style-type: none"> • Increase tensile strength, good radial force -> thin strut (oriented PLLA, Arterius technology)
<ul style="list-style-type: none"> ○ Quadratic strut <ul style="list-style-type: none"> ○ Difficult to embed ○ Disturb laminar flow 	<ul style="list-style-type: none"> • Circular strut (Manli technology) <ul style="list-style-type: none"> • Easy to embed • Less disturbance of laminar flow
<ul style="list-style-type: none"> ○ Increase local viscosity and thrombogenicity ○ Main determinant of neointimal thickness and LA reduction 	<ul style="list-style-type: none"> • Use of biodegradable material non-thrombogenic: Magnesium
<ul style="list-style-type: none"> ○ Slow down the cell coverage 	<ul style="list-style-type: none"> • Circular strut
<ul style="list-style-type: none"> ○ Late structural discontinuity (dismantling) 	<ul style="list-style-type: none"> • Faster bioresorption (Manli technology)


Embedment depth stratified by underlying plaque type



Only Absorb BVS arm: L = 79 / Strut N= 667




Sotomi Y, Serruys PW et al. *Circ J.* 2016;80(11):2317-2326.



*strut thickness of BVS

Fusion of Angio and OCT, pulsatile flow, non-Newtonian shear stress immediately after Absorb implantation in a human being



Tenekecioglu E, Poon E, et al. Serruys PW.

The Nidus for Possible Thrombus Formation: Insight From the Microenvironment of Bioresorbable Vascular Scaffold.

JACC Cardiovasc Interv. 2016 Oct 24;9(20): 2167-2168.



Tenekecioglu E, Serruys PW et al.

Assessment of the hemodynamic characteristics of Absorb BVS in a porcine coronary artery model.

Int J Cardiol. 2017 Jan 15; 227:467-473.






Non-Newtonian (cell tracking) shear stress and viscosity in early systole

Navier Stokes (ESS) and Quemada (viscosity) equations




- **Pink fuzzy areas are regions with low shear stress with high viscosity**

Comparison of Acute Thrombogenicity for Metallic and Polymeric Bioabsorbable Scaffolds: Magmaris vs ABSORB vs Orsiro in a Porcine Arteriovenous Shunt Model




Thick strut is also the main determinant of neointimal thickness and LA reduction


Biplane Angiography and FD-OCT (Terumo): 3D reconstruction of RCA with BVS




INVERSE RELATIONSHIP BETWEEN STRUT PROTRUSION AND SHEAR STRESS IN ABSORB BIORESORBABLE SCAFFOLD



INVERSE RELATIONSHIP SHEAR STRESS AND NEOINTIMAL THICKNESS IN ABSORB BIORESORBABLE SCAFFOLD





The effect of thick (150 μm), quadratic strut on flow reversal, recirculation, fibrin deposition and endothelial migration and coverage



Circular strut (next slide)

0-24 hr


40-72 hr



How improved scaffold technology can reduce clinical complication?






Shortcomings	Possible solution
<ul style="list-style-type: none"> ○ Low tensile strength, low radial force, recoil <> ○ thick strut, wide footprint 	<ul style="list-style-type: none"> • Increase tensile strength, good radial force -> thin strut (oriented PLLA, Arterius technology)
<ul style="list-style-type: none"> ○ Quadratic strut <ul style="list-style-type: none"> ○ Difficult to embed ○ Disturb laminar flow 	<ul style="list-style-type: none"> • Circular strut (Manli technology) <ul style="list-style-type: none"> • Easy to embed • Less disturbance of laminar flow
<ul style="list-style-type: none"> ○ Increase local viscosity and thrombogenicity ○ Main determinant of neointimal thickness and LA reduction 	<ul style="list-style-type: none"> • Use of biodegradable material non-thrombogenic: Magnesium
<ul style="list-style-type: none"> ○ Slow down the cell coverage 	<ul style="list-style-type: none"> • Circular strut
<ul style="list-style-type: none"> ○ Late structural discontinuity (dismantling) 	<ul style="list-style-type: none"> • Faster bioresorption (Manli technology)

CIRCULAR STRUTS (mono fiber) PENETRATE INTO THE VESSEL WALL BETTER THAN THE *QUADRATIC* STRUTS



$$p(\rho) = \frac{2\mu h}{\pi(1-\nu)\sqrt{a^2 - \rho^2}}$$




Inverse relationship between contact radius and contact pressure



In a porcine model (n=8) and human randomized trial (n=20), strut protrusion and shear stress differentiated the two devices

MIRAGE BRMS

ABSORB BVS



Note the intense recirculation area behind the quadratic strut in flow model

Tenekecioglu E, Serruys PW, et al. Int J Cardiol. 2017;227:467-473.

Tenekecioglu E, Serruys PW, et al. Int J Cardiovasc Imaging. 2017;33:1313-1321.



Tenekecioglu E, Serruys PW et al. JACC: Card Interventions, July 2017

How improved scaffold technology can reduce clinical complication?

Shortcomings	Possible solution
<ul style="list-style-type: none"> ○ Low tensile strength, low radial force, recoil <> ○ thick strut, wide footprint 	<ul style="list-style-type: none"> • Increase tensile strength, good radial force -> thin strut (oriented PLLA, Arterius technology)
<ul style="list-style-type: none"> ○ Quadratic strut <ul style="list-style-type: none"> ○ Difficult to embed ○ Disturb laminar flow 	<ul style="list-style-type: none"> • Circular strut (Manli technology) <ul style="list-style-type: none"> • Easy to embed • Less disturbance of laminar flow
<ul style="list-style-type: none"> ○ Increase local viscosity and thrombogenicity ○ Main determinant of neointimal thickness and LA reduction 	<ul style="list-style-type: none"> • Use of biodegradable material non-thrombogenic: Magnesium
<ul style="list-style-type: none"> ○ Slow down the cell coverage 	<ul style="list-style-type: none"> • Circular strut
<ul style="list-style-type: none"> ○ Late structural discontinuity (dismantling) 	<ul style="list-style-type: none"> • Faster bioresorption (Manli technology)


Late discontinuities of a scaffold in human on OCT 2D-3D

Baseline - 1 year - 2 years



Frequency of late discontinuities between 2 and 3 years (**truly serial** analysis at lesion level)


-by courtesy of Prof. Kimura





The rate of biodegradation has important impact on bioresorption and dismantling

ABSORB

Post-Procedure



MIRAGE




THE GOOD NEWS...

- **Long-term (5 years) remodeling***
 - **Homogenizes shear stress towards physiological value of shear stress (>1 Pa)**
 - **Eliminates the corrugate appearance of the scaffold (smooth surface at 5 years) ****
 - **Self-corrects the procedural overexpansion or underexpansion created by the operator ****

• Serruys et al. Glagovian Appraisal of Arterial Remodeling in Absorb Bioresorbable Scaffolds and Xience Metallic Stents. J Am Coll Cardiol. 2017;70:60-74.

** Serruys et al. Dmax for sizing, PSP-1, PSP-2, PSP-3 or OCT guidance: interventionalist's jargon or indispensable implantation techniques for short- and long-term outcomes of Absorb BRS?. EuroIntervention. 2017;12:2047-2056.

FLYING THROUGH VIEW OF THE SHEAR STRESS DISTRIBUTION AT END SYSTOLE IN THE LUMINAL SURFACE OF CASE 97969-005 POST-IMPLANTATION AND AT 5-YEAR FOLLOW UP



- **Homogenizes shear stress towards physiological value of shear stress (>1 Pa)**
- **Eliminates the corrugate appearance of the scaffold (smooth surface at 5 years)**

Serruys, Onuma. EuroIntervention. 2017;12(17):2047-2056.

Thondapu V, Tenekecioglu E, Serruys PW et al. Eur Heart J Cardiovasc Imaging. 2017 Jul.

How to accelerate strut encapsulation in vessel wall and avoid the transient consequence of discontinuity???

- ✓ Reducing the protrusion of the strut (stronger and thinner strut) **-done-**
- ✓ Better embedment of the struts **-done-**
- ✓ Changing the quadratic shape of the strut into a circular one **-done-**
- ✓ Faster Bioresorption without inducing an inflammatory vasculitis **-major dilemma-**

... will result in fast tissue coverage and firm encapsulation of the struts into the vessel wall.

**-The future is bright!-
There is room for progress!**



THE UNIVERSITY OF
MELBOURNE

Erasmus MC
Universitair Medisch Centrum Rotterdam



THE UNIVERSITY OF
MELBOURNE

Erasmus MC
Universitair Medisch Centrum Rotterdam



THANKS...



THE UNIVERSITY OF
MELBOURNE



THE UNIVERSITY OF
MELBOURNE

ACADEMIC
CORELAB
CARDIOLYSIS
Clinical Trial Management - Core Laboratories



Erasmus MC
Universitair Medisch Centrum Rotterdam



Bioresorbable Scaffolds

From Basic Concept
to Clinical Applications



Yoshinobu Onuma | Patrick Serruys

SECTION EDITORS:

A. Abizaid · A. Columbo · R. Gao · M. Haude · A. Lafont
J. Ormiston · A. Seth · G. Stone · S. Verheye · R. Waksman



456pp, 750 illustrations, eBook: 978-1-498-77977-7



Bioresorbable Scaffolds

Edited by:

Patrick W.J.C. Serruys, Imperial College, Erasmus University
Yoshinobu Onuma, Erasmus University

TABLE OF CONTENTS:

- Introduction
- Principles of bioresorption, vascular application
- From bench test to preclinical assessment
- Lesson learned from preclinical assessment
- Imaging to evaluate the bioresorbable scaffold
- Clinical evidence of randomised and non randomised trials
- Clinical evidence in specific patient subsets - personal perspective
- Complications (incidence, diagnosis, potential mechanisms and treatment)
- Tips and tricks to implant BRS
- Emerging technologies (Pre-CE mark, Pre FDA, pre PMDA and pre CFDA)

For more information visit:

www.crcpress.com/9781498779746